Neuronetics, Inc. STIM
1.25 USD -0.14 (-10.07%)
Regular-session close
1.28 +0.03 +2.78%
After hours · Nov 16, 5:54 PM ET
1.25 Day range 1.41
0.80 52-week range 3.44
- YTD
- -9.42%
- 1 year
- -37.19%
News
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) stock increased by 13.2% to $1.29 during Wednesday's pre-market session. The company's market cap stands at $5.4 million. The company's, Q2 earnings came…
globenewswire.com Neuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common Stock MALVERN, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the pricing of its previously announced underwritten public offering of its common…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 13.9% to $2.2 during Tuesday's after-market session. The company's market cap stands at $73.3 million. Longeveron (NASDAQ:LGVN) stock…benzinga.com Neuronetics Announces Credit Agreement Amendments And Public Offering Of Shares; Size Not Disclosed Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics"), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook…
globenewswire.com Neuronetics Announces Proposed Public Offering of Common Stock MALVERN, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology…benzinga.com B. Riley Securities Maintains Buy on Neuronetics, Raises Price Target to $6 B. Riley Securities analyst Madison El-Saadi maintains Neuronetics (NASDAQ:STIM) with a Buy and raises the price target from $5 to $6.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma…
benzinga.com Neuronetics Q3 2026 Earnings Call Transcript Neuronetics (NASDAQ:STIM) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…benzinga.com Neuronetics Q3 EPS $(0.02) Beats $(0.09) Estimate, Sales $41.962M Beat $40.425M Estimate Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.09) by 77.78 percent. This is a 84.62 percent increase over losses of $(0.13)…
benzinga.com Neuronetics Affirms FY2026 Sales Guidance of $160.000M-$164.000M vs $162.025M Est Neuronetics (NASDAQ:STIM) affirms FY2026 sales outlook from $160.000 million-$164.000 million to $160.000 million-$164.000 million vs $162.025 million estimate.
